Buduj odporność z mikrobiomem! Specjalnie dobrane składniki, które wspierają aktywację jelitowego układu odpornościowego.
Laktoferyna
* Berlutti, F., Pantanella, F., Natalizi, T., Frioni, A., Paesano, R., Polimeni, A., & Valenti, P. (2011). Antiviral properties of lactoferrin—a natural immunity molecule. Molecules, 16(8), 6992-7018.
** Hao, L., Shan, Q., Wei, J., Ma, F., & Sun, P. (2019). Lactoferrin: major physiological functions and applications. Current Protein and Peptide Science, 20(2), 139-144.
*** Lauterbach, R., Kamińska, E., Michalski, P., & Lauterbach, J. P. (2016). Laktoferyna–glikoproteina o dużym potencjale terapeutycznym. DEVELOPMENTAL, 118.
Bifidobacterium infantis
* Scully, P., Macsharry, J., O’Mahony, D., Lyons, A., O’Brien, F., Murphy, S., … & O’Mahony, L. (2013). Bifidobacterium infantis suppression of Peyer’s patch MIP-1α and MIP-1β secretion during Salmonella infection correlates with increased local CD4+ CD25+ T cell numbers. Cellular immunology, 281(2), 134-140.
** O’Hara, A. M., O’Regan, P., Fanning, Á., O’Mahony, C., MacSharry, J., Lyons, A., … & Shanahan, F. (2006). Functional modulation of human intestinal epithelial cell responses by Bifidobacterium infantis and Lactobacillus salivarius. Immunology, 118(2), 202-215.
*** Lyseng-Williamson, K. A. (2017). Bifidobacterium infantis 35624 as a probiotic dietary supplement: a profile of its use. Drugs & Therapy Perspectives, 33(8), 368-374.
**** Ewaschuk, J. B., Diaz, H., Meddings, L., Diederichs, B., Dmytrash, A., Backer, J., … & Madsen, K. L. (2008). Secreted bioactive factors from Bifidobacterium infantis enhance epithelial cell barrier function. American journal of physiology-gastrointestinal and liver physiology, 295(5), G1025-G1034.
***** Whorwell, P. J., Altringer, L., Morel, J., Bond, Y., Charbonneau, D., O’mahony, L., … & Quigley, E. M. (2006). Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Official journal of the American College of Gastroenterology| ACG, 101(7), 1581-1590.
Lactobacillus plantarum
- * Ducrotté, P., Sawant, P., & Jayanthi, V. (2012). Clinical trial: Lactobacillus plantarum 299v (DSM 9843) improves symptoms of irritable bowel syndrome. World journal of gastroenterology: WJG, 18(30), 4012. de Vos, P., Mujagic, Z., de Haan, B. J., Siezen, R. J., Bron, P. A.
- ** Meijerink, M., … & Troost, F. J. (2017). Lactobacillus plantarum strains can enhance human mucosal and systemic immunity and prevent non-steroidal anti-inflammatory drug induced reduction in T regulatory cells. Frontiers in immunology, 8, 1000.
Lactobacillus rhamnosus
* Segers, M. E., & Lebeer, S. (2014). Towards a better understanding of Lactobacillus rhamnosus GG-host interactions. Microbial cell factories, 13(1), 1-16.
** Fong, F. L. Y., Kirjavainen, P. V., & El-Nezami, H. (2016). Immunomodulation of Lactobacillus rhamnosus GG (LGG)-derived soluble factors on antigen-presenting cells of healthy blood donors. Scientific reports, 6(1), 1-8.
*** Yan, F., & Polk, D. B. (2012). Lactobacillus rhamnosus GG: an updated strategy to use microbial products to promote health. Functional food reviews (Print), 4(2), 77.
**** Pedersen, N., Andersen, N. N., Végh, Z., Jensen, L., Ankersen, D. V., Felding, M., … & Munkholm, P. (2014). Ehealth: low FODMAP diet vs Lactobacillus rhamnosus GG in irritable bowel syndrome. World Journal of Gastroenterology: WJG, 20(43), 16215.
Dozowanie
Przechowywanie
Środki ostrożności
Bez konserwantów
Bez sztucznych barwników
Bez GMO
Bez herbicydów i innych pestycydów
Bez glutenu
16.1 „de Vos P, Mujagic Z, de Haan BJ, et al. Lactobacillus plantarum Strains Can Enhance Human Mucosal and Systemic Immunity and Prevent Non-steroidal Anti-inflammatory Drug Induced Reduction in T Regulatory Cells. Front Immunol. 2017;8:1000. Published 2017 Aug 23. doi:10.3389/fimmu.2017.01000
Kruzel ML, Zimecki M, Actor JK. Lactoferrin in a Context of Inflammation-Induced Pathology. Front Immunol. 2017;8:1438. Published 2017 Nov 6. doi:10.3389/fimmu.2017.01438”
16.2 Han X, Lee A, Huang S, Gao J, Spence JR, Owyang C. Lactobacillus rhamnosus GG prevents epithelial barrier dysfunction induced by interferon-gamma and fecal supernatants from irritable bowel syndrome patients in human intestinal enteroids and colonoids. Gut Microbes. 2019;10(1):59-76. doi:10.1080/19490976.2018.1479625
16.3 Lebeer S, Claes I, Tytgat HL, et al. Functional analysis of Lactobacillus rhamnosus GG pili in relation to adhesion and immunomodulatory interactions with intestinal epithelial cells. Appl Environ Microbiol. 2012;78(1):185-193. doi:10.1128/AEM.06192-11
16.4 Vega-Bautista A, de la Garza M, Carrero JC, Campos-Rodríguez R, Godínez-Victoria M, Drago-Serrano ME. The Impact of Lactoferrin on the Growth of Intestinal Inhabitant Bacteria. Int J Mol Sci. 2019;20(19):4707. Published 2019 Sep 23. doi:10.3390/ijms20194707
Konstanti P, van Splunter M, van den Brink E, et al. The Effect of Nutritional Intervention with Lactoferrin, Galactooligosacharides and Vitamin D on the Gut Microbiota Composition of Healthy Elderly Women. Nutrients. 2022;14(12):2468. Published 2022 Jun 14. doi:10.3390/nu14122468
Nie ma jeszcze żadnych opinii.